Related Experiment Videos
Brain metastases in patients with differentiated thyroid carcinoma
P Hjiyiannakis1, S Jefferies, C L Harmer
1Royal Marsden Hospital, London, UK.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|January 1, 1996
Summary
Brain metastases are a rare complication of differentiated thyroid carcinoma. This study found a poor prognosis for patients diagnosed with brain metastases, with limited survival rates.
Area of Science:
- Oncology
- Neurology
- Endocrinology
Background:
- Differentiated thyroid carcinoma (DTC) is the most common type of thyroid cancer.
- Brain metastases are an uncommon but serious complication of DTC.
- Understanding the prognosis and treatment of DTC brain metastases is crucial.
Observation:
- A retrospective review identified six patients with DTC who developed brain metastases between 1936 and 1991.
- These patients were part of a larger cohort of 649 DTC cases.
- The study was conducted at the Royal Marsden Hospital.
Findings:
- The prognosis for patients with DTC brain metastases was poor.
- Five out of six patients survived between 1 to 19 months after diagnosis.
- One patient remained alive at 18 months post-diagnosis.
Implications:
- The findings highlight the aggressive nature of DTC when it metastasizes to the brain.
- A dosimetric approach to treatment may offer a way to personalize and optimize care.
- Further research into optimal management strategies for DTC brain metastases is warranted.